Medios AG resolves on capital increase against cash contributions of up to almost 10% of the share capital

Medios AG / Key word(s): Capital Increase
Medios AG resolves on capital increase against cash contributions of up to almost 10% of the share capital

03-Jun-2020 / 17:40 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER COUNTRIES WHERE SUCH DISTRIBUTION OR PUBLICATION MIGHT BE UNLAWFUL
 

Medios AG resolves on capital increase against cash contributions of up to almost 10% of the share capital

Berlin, 3 June 2020 - Today, the Management Board of Medios AG (the 'Company') has resolved, with the consent of the Supervisory Board, to increase the share capital against cash contributions, making partial use of the Authorized Capital 2018 and 2019. Accordingly, the Company's share capital of currently €14,628,590.00 is expected to increase by up to almost 10% by issuing up to 1,456,401 new no-par value bearer shares ('New Shares'). The statutory subscription rights of the shareholders are excluded. The New Shares carry the same rights as the existing shares with the ISIN DE000A1MMCC8 and will be admitted to trading on the regulated market of the Frankfurt Stock Exchange, without a prospectus, with simultaneous admission to the sub-segment of the regulated market with additional post-admission obligations (Prime Standard).

The New Shares are to be offered for purchase exclusively to institutional investors in an international private placement by means of an accelerated bookbuilding process.

The placement price and the exact number of New Shares to be issued will be determined by the Management Board with the approval of the Supervisory Board after completion of the placement procedure. The first trading day of the New Shares is expected to be June 5, 2020. Delivery of the New Shares is envisaged for Monday, 8 June 2020.

Notifying person: Matthias Gärtner, Chief Financial Officer (CFO) of Medios AG

Contact
Medios AG, Heidestraße 9, 10557 Berlin, Germany
Phone: +49 30 232 5668 00; Fax: +49 30 232 5668 01
E-mail: ir@medios.ag; www.medios.ag

The private placement will commence immediately following the publication of this announcement. The order book is expected to close on 4 June 2020 prior to the start of trading, although the Company reserves the right to close the order book at any time earlier.

The expected net proceeds from the offering will be used to further expand Medios' leading position as provider of specialty pharma solutions through both organic and external growth opportunities. The additional funds allow the Company to tap attractive growth potential in additional indications, to further expand its existing partner network, and to substantially increase its production capacity for patient-specific medication. The Company continuously monitors the market to capitalize on external growth opportunities and intends to play an active role in the ongoing market consolidation process in order to accelerate its proven growth strategy.

Following the successful placement of all New Shares, the free float of Medios AG will increase from currently around 62% to up to around 66% of the share capital, which will help to further improve the liquidity of the stock and additionally support the admission to the SDAX.

The company has agreed to a lock-up period of 90 days subject to customary market exceptions.

Joh. Berenberg, Gossler & Co. KG is acting as Sole Global Coordinator and Sole Bookrunner for the private placement.

-------------------

About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As a specialist for the provision of Specialty Pharma drugs to patients, GMP-certified provider of patient-specific therapies and innovative analytical methods, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Usually, Specialty Pharma drugs are high-priced medicines for rare and/or chronic diseases. Patient-specific therapies are, for example, infusions that are compiled and produced on the basis of individual diseases and parameters like body weight and surface. In the field of drug safety, NIR spectroscopic analysis methods (NIR: Near infrared) are used to distinguish marketable finished drugs from drug counterfeits. It is Medios' aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany's first publicly listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8, DE000A288821) are listed in the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

Contact
Medios AG
Claudia Nickolaus
Head of Investor-/ Public Relations
Heidestraße 9
10557 Berlin
Germany
Phone: +49 30 232566832
Fax: +49 30 232566801
E-mail: c.nickolaus@medios.ag
www.medios.ag

Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany
Phone: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

Disclaimer
This notification is a mandatory notification according to Art. 17 MAR. Medios AG is solely responsible for the content of this announcement. As always, the assessments contained herein are subject to the reservations stated below.

Reservation on future statements/no obligation to update
This release contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated due to various risk factors and uncertainties, including changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Medios AG assumes no responsibility whatsoever to update the forward-looking statements contained in this release.

Note
This release may not be distributed or published in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other countries where such publication may be unlawful. The distribution of this publication may be subject to legal restrictions in some countries and anyone in possession of this document or the information referred to herein should inform themselves about and observe any such restrictions. Failure to comply with such restrictions may constitute a violation of capital market laws of such countries.

This announcement is neither an offer nor a solicitation to subscribe to or purchase securities of Medios AG in the United States of America, Germany or any other country. No public offer has been or will be made or prospectus published in connection with this transaction.

Neither this publication nor its contents may be used as the basis for an offer in any country. The aforementioned securities may not be sold or offered for sale in the United States of America absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the 'Securities Act'). The securities of Medios AG are not and will not be registered under the Securities Act.

This announcement does not constitute a recommendation regarding the placement of the securities described in this announcement. Investors should consult a professional advisor as to the suitability of the offer for the person concerned.

In the United Kingdom, this publication is directed only at (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'), as amended, or (ii) persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, partnerships, etc.) (such persons together being referred to as 'Relevant Persons'). No persons other than Relevant Persons may refer to or rely on this publication. Any investment or investment opportunity referred to in this publication is available only to Relevant Persons and will be engaged in only with Relevant Persons.

The offer referred to herein, which is made in Member States of the European Economic Area and the United Kingdom (each a 'Relevant Member State') is only addressed to 'qualified investors' within the meaning of Article 2 (e) of the Prospectus Regulation ('Qualified Investors'). For these purposes, the term 'Prospectus Regulation' means Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC, and also includes the delegated regulations in this regard.

No measures have been taken that would permit the offer of the securities, their acquisition or the distribution of this publication in countries where this is not permitted. Anyone who comes into possession of this publication must inform themselves about any restrictions and observe them.

Miscellaneous
This publication is neither an offer to sell nor a solicitation to buy securities. This announcement may not be distributed or published in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other countries in which such publication may be unlawful. This announcement does not constitute a recommendation to buy or sell the securities described in this announcement.

03-Jun-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de